Literature DB >> 35788883

Cardiomyocyte Maturation-the Road is not Obstructed.

Yaning Wang1, Miao Yu1, Kaili Hao1, Wei Lei1, Mingliang Tang2, Shijun Hu3.   

Abstract

Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) represent one of the most promising ways to treat cardiovascular diseases. High-purity cardiomyocytes (CM) from different cell sources could be obtained at present. However, the immature nature of these cardiomyocytes hinders its further clinical application. From immature to mature state, it involves structural, functional, and metabolic changes in cardiomyocytes. Generally, two types of culturing (2D and 3D) systems have been reported to induce cardiomyocyte maturation. 2D culture mainly achieves the maturation of cardiomyocytes through long-term culture, co-culture, supplementation of small molecule compounds, and the application of biophysical cues. The combined use of biomaterial's surface topography and biophysical cues also facilitates the maturation of cardiomyocytes. Cardiomyocyte maturation is a complex process involving many signaling pathways, and current methods fail to fully reproduce this process. Therefore, analyzing the signaling pathway network related to the maturation and producing hPSC-CMs with adult-like phenotype is a challenge. In this review, we summarized the structural and functional differences between hPSC-CMs and mature cardiomyocytes, and introduced various methods to induce cardiomyocyte maturation.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiomyocyte; Maturation; Pluripotent stem cell

Year:  2022        PMID: 35788883     DOI: 10.1007/s12015-022-10407-y

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  107 in total

Review 1.  Cardiac macrotissues-on-a-plate models for phenotypic drug screens.

Authors:  Tim Meyer; Malte Tiburcy; Wolfram-Hubertus Zimmermann
Journal:  Adv Drug Deliv Rev       Date:  2019-03-19       Impact factor: 15.470

Review 2.  The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing.

Authors:  Lingqun Ye; Xuan Ni; Zhen-Ao Zhao; Wei Lei; Shijun Hu
Journal:  J Cardiovasc Transl Res       Date:  2018-05-29       Impact factor: 4.132

Review 3.  Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as Models for Cardiac Channelopathies: A Primer for Non-Electrophysiologists.

Authors:  Priyanka Garg; Vivek Garg; Rajani Shrestha; Michael C Sanguinetti; Timothy J Kamp; Joseph C Wu
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

4.  Genome Editing of Lineage Determinants in Human Pluripotent Stem Cells Reveals Mechanisms of Pancreatic Development and Diabetes.

Authors:  Zengrong Zhu; Qing V Li; Kihyun Lee; Bess P Rosen; Federico González; Chew-Li Soh; Danwei Huangfu
Journal:  Cell Stem Cell       Date:  2016-04-28       Impact factor: 24.633

Review 5.  Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine.

Authors:  Elena Matsa; John H Ahrens; Joseph C Wu
Journal:  Physiol Rev       Date:  2016-07       Impact factor: 37.312

Review 6.  Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure.

Authors:  A M Gerdes; J M Capasso
Journal:  J Mol Cell Cardiol       Date:  1995-03       Impact factor: 5.000

Review 7.  Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics.

Authors:  David T Paik; Mark Chandy; Joseph C Wu
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 8.  Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering.

Authors:  Mounica Yanamandala; Wuqiang Zhu; Daniel J Garry; Timothy J Kamp; Joshua M Hare; Ho-Wook Jun; Young-Sup Yoon; Nenad Bursac; Sumanth D Prabhu; Gerald W Dorn; Roberto Bolli; Richard N Kitsis; Jianyi Zhang
Journal:  J Am Coll Cardiol       Date:  2017-08-08       Impact factor: 24.094

Review 9.  Clinical Trial in a Dish: Using Patient-Derived Induced Pluripotent Stem Cells to Identify Risks of Drug-Induced Cardiotoxicity.

Authors:  Chi Keung Lam; Joseph C Wu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-01-21       Impact factor: 8.311

10.  Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates.

Authors:  Yen-Wen Liu; Billy Chen; Xiulan Yang; James A Fugate; Faith A Kalucki; Akiko Futakuchi-Tsuchida; Larry Couture; Keith W Vogel; Clifford A Astley; Audrey Baldessari; Jason Ogle; Creighton W Don; Zachary L Steinberg; Stephen P Seslar; Stephanie A Tuck; Hiroshi Tsuchida; Anna V Naumova; Sarah K Dupras; Milly S Lyu; James Lee; Dale W Hailey; Hans Reinecke; Lil Pabon; Benjamin H Fryer; W Robb MacLellan; R Scott Thies; Charles E Murry
Journal:  Nat Biotechnol       Date:  2018-07-02       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.